V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330005300 | 330002539 | null | null | null | null | 2016-03-14 | Doxorubicin + Olaratumab | null | null | 330022873 | DOCETAXEL + GEMCITABINE |
| 330005301 | 330002539 | null | null | Curative (C) | 2017-10-23 | 2017-10-24 | GC Int Guide Excranial GermCell JEB | 02 | N | 330022873 | CISPLATIN + DOX + ETOPOSIDE + MITOTANE |
| 330005302 | 330002539 | 1.61 | null | Palliative (P) | 2017-02-06 | 2017-02-06 | CLADRIBINE + CYTARABINE + DAUNORUBICIN | N | null | 330022873 | CISPLATIN + FLUOROURACIL + RT |
| 330005303 | 330011464 | null | 48.2 | Curative (C) | 2014-11-29 | 2014-11-30 | Hydroxycarbamide | 2 | N | 330022881 | AML19 TRIAL |
| 330005304 | 330002540 | 1.62 | null | null | null | 2016-07-04 | Docetaxel | Y | N | 330022883 | CHLORAMBUCIL + RITUXIMAB |
| 330005305 | 330002541 | 1.6 | 65 | Disease modification (D) | 2016-01-26 | 2016-02-24 | Ipilimumab | N | N | 330022888 | HYDROXYCARBAMIDE |
| 330005306 | 330002541 | 1.88 | 65.8 | Curative (C) | 2017-01-29 | 2017-04-30 | EDP + MITOTANE | N | N | 330022888 | CISPLATIN + DOX + ETOPOSIDE |
| 330005307 | 330002542 | null | null | Palliative (P) | null | 2016-05-12 | EC | N | N | 330022893 | RUXOLITINIB |
| 330005308 | 330002543 | 1.7 | 61.5 | Palliative (P) | 2017-03-09 | 2017-03-19 | AML 19 TRIAL | 2 | N | 330022900 | CETUXIMAB + CISPLATIN + FLUOROURACIL |
| 330005309 | 330002543 | 1.64 | 96 | Palliative (P) | 2016-01-06 | 2016-01-28 | Doxorubicin + Olaratumab | 2 | N | 330022900 | PACLITAXEL |
| 330005310 | 330002543 | null | 73.5 | Palliative (P) | null | 2014-09-21 | CAPECITABINE + MITOMYCIN + RT | null | null | 330022900 | CYCLOPHOSPHAMIDE + TOPOTECAN |
| 330005311 | 330002543 | null | 104.1 | Palliative (P) | 2014-10-17 | 2014-10-25 | Chlorambucil | N | N | 330022900 | BORTEZOMIB |
| 330005312 | 330002543 | 0 | null | null | null | 2016-04-16 | AML Int Guide ADE 10+3+5 (1) | null | null | 330022900 | CARBOPLATIN + VINORELBINE |
| 330005313 | 330002544 | 1.68 | 61.5 | Palliative (P) | 2014-01-18 | 2014-01-18 | Doxorubicin + Olaratumab | N | N | 330022929 | CISPLATIN + VINORELBINE |
| 330005314 | 330002544 | 1.66 | 84.4 | Curative (C) | 2013-12-27 | 2013-12-27 | VAC | 02 | N | 330022929 | CISPLATIN + FLUOROURACIL + RT |
| 330005315 | 330010016 | 1.63 | 52.3 | Curative (C) | 2017-05-25 | 2017-05-26 | CASPS TRIAL | 2 | N | 330022938 | OXALIPLATIN + MDG |
| 330005316 | 330011466 | 1.73 | 108.9 | Palliative (P) | 2017-01-04 | 2017-01-09 | CETUXIMAB + CISPLATIN + FU | 02 | N | 330022958 | CISPLATIN + DOCETAXEL |
| 330005317 | 330002545 | 1.54 | null | Curative (C) | 2017-09-06 | 2017-09-22 | IBRUTINIB | 02 | N | 330022963 | OXALIPLATIN + MDG |
| 330005318 | 330007399 | 0 | 86 | Palliative (P) | 2017-08-05 | 2017-08-05 | CISPLATIN + DOXORUBICIN + ETOPOSIDE | 02 | Y | 330022970 | EP/EMA |
| 330005319 | 330010017 | 1.7 | 81.1 | null | 2017-09-26 | 2017-10-01 | Azacitidine | 02 | N | 330022975 | CYTARABINE INTRATHECAL |
| 330005321 | 330002547 | 1.7 | 71 | Curative (C) | 2017-09-06 | 2017-09-18 | AML 19 TRIAL | 1 | N | 330022977 | UKALL2011 |
| 330005322 | 330002548 | 1.85 | 69.9 | Palliative (P) | 2017-05-28 | 2017-06-02 | AML16 Low Dose Cytarabine | N | N | 330022979 | DABRAFENIB |
| 330005323 | 330002548 | 1.6 | 79.3 | Neo-adjuvant (N) | null | 2017-07-18 | AML17 TRIAL | N | N | 330022979 | CARBOPLATIN + RT |
| 330005324 | 330002549 | 0 | null | null | 2015-03-19 | 2015-03-31 | BUSULFAN + FLUDARABINE + METHOTREXATE | null | null | 330022992 | VIDE |
| 330005325 | 330002550 | 0 | 10 | Curative (C) | 2014-11-23 | 2014-11-23 | Cisplatin + Pemetrexed | N | N | 330022993 | TEMOZOLOMIDE |
| 330005326 | 330002551 | 1.82 | 80 | Curative (C) | 2014-04-16 | 2014-04-23 | IPILIMUMAB + NIVOLUMAB | N | N | 330022997 | BEP |
| 330005327 | 330002551 | 1.65 | 87.3 | Palliative (P) | 2017-01-22 | 2017-02-24 | VIDE | N | Y | 330022997 | DOCETAXEL |
| 330005330 | 330010018 | 1.62 | 60.6 | Adjuvant (A) | 2017-03-10 | 2017-03-21 | CNS HGG Temozolomide maintenance | N | N | 330023014 | CYTARABINE |
| 330005331 | 330002553 | 1.78 | 86.9 | Curative (C) | 2017-02-03 | 2017-02-04 | Cisplatin + Pemetrexed | N | N | 330023015 | VINCRISTINE |
| 330005332 | 330002554 | null | 79.6 | Curative (C) | 2018-05-28 | 2018-05-31 | CNS HGG Temozolomide maintenance | N | null | 330023021 | CAPECITABINE + CARBOPLATIN |
| 330005333 | 330002555 | null | 96.7 | Curative (C) | null | 2013-06-17 | Doxorubicin + Olaratumab | null | null | 330023031 | PEMBROLIZUMAB |
| 330005334 | 330002555 | 1.76 | 69 | Palliative (P) | 2015-07-03 | 2015-07-30 | PCV | 02 | N | 330023031 | PACLITAXEL |
| 330005335 | 330010019 | 1.77 | null | Adjuvant (A) | 2013-05-03 | 2013-05-03 | Capecitabine + Cisplatin | null | null | 330023042 | FCR |
| 330005336 | 330010019 | 1.6 | 68 | Curative (C) | 2014-03-20 | 2014-10-22 | Etoposide + Ifosfamide (3 days) | N | N | 330023042 | PEMBROLIZUMAB |
| 330005337 | 330010019 | 1.58 | 66 | Curative (C) | 2013-02-11 | 2013-02-25 | CVP | N | Y | 330023042 | VIDE |
| 330005338 | 330010019 | 0 | null | Curative (C) | 2017-02-07 | 2017-02-09 | Etoposide + Ifosfamide (3 days) | 02 | N | 330023042 | IMATINIB |
| 330005339 | 330010019 | 1.55 | 51.5 | Curative (C) | 2013-07-23 | 2014-02-25 | Vinblastine weekly | N | N | 330023042 | DOCETAXEL + GEMCITABINE |
| 330005340 | 330010019 | 1.81 | null | Curative (C) | 2013-11-01 | 2013-11-01 | Hydroxycarbamide | N | N | 330023042 | CYTARABINE |
| 330005341 | 330010019 | 1.87 | 88 | Palliative (P) | 2015-10-03 | 2015-10-03 | METHOTREXATE | 02 | N | 330023042 | CAPECITABINE + CARBOPLATIN |
| 330005342 | 330010019 | 1.69 | 64 | Curative (C) | 2017-11-12 | 2017-11-16 | Doxorubicin chemoembolisation | N | N | 330023042 | IMATINIB |
| 330005343 | 330002556 | 1.55 | 50 | Palliative (P) | 2016-10-14 | 2016-10-26 | Mitotane 2g | N | N | 330023073 | DOCETAXEL + GEMCITABINE |
| 330005344 | 330002557 | 0 | 52.6 | Neo-adjuvant (N) | 2014-05-25 | 2014-06-06 | GDP | N | N | 330023077 | CAPECITABINE + CISPLATIN |
| 330005345 | 330002557 | null | null | Curative (C) | null | 2017-01-07 | VAC | N | N | 330023077 | CARBOPLATIN + RT |
| 330005346 | 330002557 | 1.82 | 68.2 | Palliative (P) | 2015-09-15 | 2015-09-23 | Cetuximab + CISPLATIN + FLUOROURACIL | N | N | 330023077 | CYTARABINE + MITOXANTRONE |
| 330005347 | 330002557 | 1.8 | 70.4 | null | 2013-10-14 | 2013-10-23 | Temozolomide + RT | N | null | 330023077 | R-EPOCH |
| 330005348 | 330002557 | 1.63 | 102.3 | Disease modification (D) | 2015-08-25 | 2015-08-31 | ALL UKALL2011 Ind A Sht Dex (PAsp) | Y | N | 330023077 | CAPECITABINE + MITOMYCIN + RT |
| 330005349 | 330002557 | 1.87 | 64.8 | Palliative (P) | 2017-02-18 | 2017-02-19 | CHLORAMBUCIL + RITUXIMAB | N | N | 330023077 | GEMCITABINE + RT |
| 330005350 | 330002557 | 1.52 | 69.8 | Curative (C) | 2016-02-18 | 2016-02-20 | Vincristine (weekly) | N | N | 330023077 | CAPECITABINE + CISPLATIN |
| 330005351 | 330013141 | 1.68 | 97.7 | Curative (C) | 2017-11-08 | 2017-11-10 | Cisplatin + Pemetrexed | 02 | N | 330023088 | ETOPOSIDE + RITUXIMAB |
| 330005352 | 330013141 | 1.51 | 14.5 | Curative (C) | 2013-01-29 | 2013-05-05 | Methotrexate Intrathecal (any age) | N | N | 330023088 | AZACITIDINE |